1. Home
  2. PBYI vs DMRC Comparison

PBYI vs DMRC Comparison

Compare PBYI & DMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • DMRC
  • Stock Information
  • Founded
  • PBYI 2010
  • DMRC 2008
  • Country
  • PBYI United States
  • DMRC United States
  • Employees
  • PBYI N/A
  • DMRC N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • DMRC EDP Services
  • Sector
  • PBYI Health Care
  • DMRC Technology
  • Exchange
  • PBYI Nasdaq
  • DMRC Nasdaq
  • Market Cap
  • PBYI 171.7M
  • DMRC 187.8M
  • IPO Year
  • PBYI N/A
  • DMRC N/A
  • Fundamental
  • Price
  • PBYI $4.56
  • DMRC $8.58
  • Analyst Decision
  • PBYI Strong Buy
  • DMRC Strong Buy
  • Analyst Count
  • PBYI 1
  • DMRC 1
  • Target Price
  • PBYI $7.00
  • DMRC $30.00
  • AVG Volume (30 Days)
  • PBYI 980.5K
  • DMRC 259.2K
  • Earning Date
  • PBYI 11-06-2025
  • DMRC 08-14-2025
  • Dividend Yield
  • PBYI N/A
  • DMRC N/A
  • EPS Growth
  • PBYI 434.29
  • DMRC N/A
  • EPS
  • PBYI 0.97
  • DMRC N/A
  • Revenue
  • PBYI $238,062,000.00
  • DMRC $35,479,000.00
  • Revenue This Year
  • PBYI N/A
  • DMRC N/A
  • Revenue Next Year
  • PBYI N/A
  • DMRC N/A
  • P/E Ratio
  • PBYI $4.75
  • DMRC N/A
  • Revenue Growth
  • PBYI 8.63
  • DMRC N/A
  • 52 Week Low
  • PBYI $2.25
  • DMRC $7.77
  • 52 Week High
  • PBYI $6.07
  • DMRC $48.32
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 47.28
  • DMRC 39.27
  • Support Level
  • PBYI $4.93
  • DMRC $8.21
  • Resistance Level
  • PBYI $5.22
  • DMRC $8.93
  • Average True Range (ATR)
  • PBYI 0.32
  • DMRC 0.50
  • MACD
  • PBYI -0.10
  • DMRC 0.08
  • Stochastic Oscillator
  • PBYI 7.37
  • DMRC 54.36

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

Share on Social Networks: